Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CHRM5 known ✓ | P08912 | 3/20 | 0.38 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.36 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3001559 | 1.00 | TDP1 (0.41) | TDP1LMNAKDM4EMAPTBLM | |
| SCHEMBL946729 | 0.98 | — | — | |
| SCHEMBL2171709 | 0.86 | CHRM5 (0.37) | LMNAKDM4EMAPTBLMPMP22 | |
| SCHEMBL10425365 | 0.84 | CHRM5 (0.43) | LMNAKDM4EMAPTBLMPMP22 | |
| N-Methylhistamine SCHEMBL25277752 | 0.82 | CYP2C9 (0.70) | TDP1CYP2C9CYP2C19TSHRMTOR | |
| SCHEMBL240920 | 0.80 | — | — | |
| SCHEMBL4300091 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL26696161 | 0.78 | TBXAS1 (0.42) | LMNAKDM4EMAPTBLMPMP22 | |
| SCHEMBL11372674 | 0.77 | L3MBTL1 (0.39) | LMNAKDM4EMAPTBLMPMP22 | |
| SCHEMBL9597203 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707867-B | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-112707867-A | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-112707867-B | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112707867-B | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112707867-B | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-112707867-A | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112707867-A | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112707867-A | Novel method for synthesizing 2- (1-methylimidazol-5-yl) ethylamine hydrochloride | 苏州莱克施德药业有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-1326850-C | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
| CN-1334811-A | Tricyclic farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |